Tag Archives: biotech

Earlier this month, we published this piece, focusing on Neovasc Inc (US) (NASDAQ:NVCN). The crux of our coverage was this: that the company was about to report its fourth quarter and full year 2016 financials, and that alongside these financials...

OXIS International, Inc. (OTCMKTS:OXIS) just announced that it has entered into a sponsored research agreement with the University of Minnesota, designed to help forward the development of one of its preclinical assets. This is a company we’ve...

Earlier on this week, we highlighted a small cap biotech called Kadmon Holdings Inc (NYSE:KDMN) as a company to watch this year. What flagged our attention was the heavy institutional interest that looked to be accruing in the stock, with big...

Towards the end of last year, we took a look at a small biotech play called Q BioMed Inc (OTCMKTS:QBIO). The company had just logged some gains, and had drawn our attention on the back of this run. At that point, Q BioMed was going for around...

For the last eighteen months, Anavex Life Sciences Corp. (NASDAQ:AVXL) has been at the the center of a great debate. From the company falling foul of an army of short sellers, to management overpaying themselves, to the science being made up,...

Bellerophon Therapeutics Inc (NASDAQ:BLPH) is all over the place at the moment. The company traded for around $.50 a share back in January, and ran up to highs of just shy of $2 a share at the beginning of this month. At the end of last week,...

Cerulean Pharma Inc (NASDAQ:CERU) just hit markets with news of a reverse merger, and the company has taken a huge hit on the back of the release. As things stand, at Tuesday market open, Cerulean is trading for a little over $1.25 a share....

Third Point, the fund run by Dan Loeb, just filed a purchase that saw the company pick up 1.48 million shares of Kadmon Holdings Inc (NYSE:KDMN) for $3.36 a piece. The buy brings Third Point’s total position to just shy of 10 million...

At the beginning of February, we took a look at development stage biotech company Pulmatrix Inc (NASDAQ:PULM) as part of this piece.  At the time, the company had just run up to the tune of 130% on the back of an expedited approval process...

Back in October, we published this piece, outlining our thoughts on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD). At the time, the company has just reported the discontinuation of its lead development program, and had collapsed on the back...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter